Arbutus Biopharma Corp. (ABUS) shares were having a good Friday, and it's not hard to see why. The clinical-stage biotech announced plans to buy back up to $230 million of its own stock through a modified Dutch auction tender offer. That's a fancy way of saying the company is giving shareholders a chance to sell their shares back at a price they choose, within a set range.
Here's how it works: Arbutus is offering between $5 and $5.75 per share in cash. Shareholders can indicate how many shares they want to sell and at what price within that range. The company then figures out the lowest price that lets it buy the shares it wants. It's a bit like a reverse auction, where the seller (the shareholder) names their price, and the company picks the lowest ones that get the job done.
The tender offer is expected to kick off around Aug. 24 and run until Sept. 29, unless the company extends or terminates it. Arbutus plans to fund the buyback with cash it already has on hand.
The Moderna Connection
CEO Lindsay Androski linked the buyback to the company's March 2026 settlement with Moderna Inc. (MRNA). Arbutus received roughly $178 million as its share of the noncontingent settlement payment, which also included reimbursement for litigation costs. The initial payment came through in July, and now some of that money is going back to shareholders.
But the legal battles aren't over. Arbutus and its exclusive licensee, Genevant Sciences, are still pursuing patent litigation against Pfizer Inc. (PFE) and BioNTech SE (BNTX) over the lipid nanoparticle technology used in COVID-19 vaccines. Genevant is a subsidiary of Roivant Sciences Ltd. (ROIV).
Beyond the courtroom, Arbutus is also working on its pipeline. The company is developing imdusiran and an oral PD-L1 inhibitor called AB-101 for chronic hepatitis B virus infection.
Stock Reaction
Investors seemed to like the news. Arbutus Biopharma shares were up 6.92% at $5.09 at the time of publication on Friday, according to market data.
It's a nice move for a stock that's been through a lot of legal ups and downs. The buyback is a clear signal that management thinks the shares are undervalued, and the Moderna settlement provides a solid chunk of cash to back that up. Whether the patent fight with Pfizer and BioNTech pays off remains to be seen, but for now, shareholders have a reason to smile.
